绥美凯治疗艾滋病的疗效怎样？

Five months after receiving formal approval from the State Food and Drug Administration (CFDA), the British pharmaceutical company GlaxoSmithKline (GSK) recently announced that its joint venture ViiV Healthcare’s new anti-AIDS drug Inbec has been officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. This time Inbec uses DTG, an integrase inhibitor, as the core drug, and a treatment plan with two backbone drugs, abacavir and lamivudine, and makes it into a single-tablet treatment for promotion, making the core drug a great improvement in HAART treatment. In addition, Inbec treatment can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, Inbec, which uses DTG integrase inhibitors as its core, has proven to be controllable in terms of drug safety.

In general, Inbec has four main advantages: 1. Excellent efficacy and significant viral suppression effect; 2. The three drugs are equally equivalent, and both newly-treated and previously treated patients have a high resistance barrier, which is not easy to lead to drug resistance; 3. It is easy to take, and only needs to be taken once a day, without considering food effects; 4. The drug has low side effects and good tolerance, and the discontinuation rate due to drug side effects is low; 5. The metabolic pathway has few interactions with other drugs.